We welcome the SMC's approval of trastuzumab deruxtecan for use on the NHS in Scotland
Responding to the Scottish Medicines Consortium’s (SMC) decision to approve trastuzumab deruxtecan (Enhertu) for use on the NHS in Scotland, Melanie Sturtevant, associate director of policy, evidence and influencing at Breast Cancer Now, said:
10 Apr 2023
Breast Cancer Now respond to NICE’s decision to approve olaparib for use on the NHS.
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now said:
06 Apr 2023
Breast Cancer Now responds to research about breast cancer risk and hormonal contraceptives
In response to research published in PLOS Medicine looking at breast cancer risk and combined and progestogen-only contraceptives, Dr Kotryna Temcinaite, head of research communications at Breast Cancer Now, said:
22 Mar 2023
Breast Cancer Now responds to the sad news of Jacqueline Gold's death
Reacting to the sad news of Jacqueline Gold’s death today, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now said:
17 Mar 2023
Breast Cancer Now responds to new research about AI and breast cancer screening
In response to a new trial using AI software within breast cancer screening at Leeds Teaching Hospitals NHS Trust*, Dr Kotryna Temcinaite, head of research communications at Breast Cancer Now, said:
06 Mar 2023
Breast Cancer Now flags concerns over findings of final PAC Report
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
01 Mar 2023
Breast Cancer Now responds to the welcome news of a secondary breast cancer audit being introduced in Northern Ireland
Responding to the news, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
22 Feb 2023
Breast Cancer Now responds to research about detecting breast cancer from fingertip smears
In response to research, published in Scientific Reports*, about detecting breast cancer from fingertip smears, Dr Kotryna Temcinaite, senior research communications manager at Breast Cancer Now, said:
20 Feb 2023
Breast Cancer Now responds to latest Breast Screening Performance Data 2021-2022
Commenting on the latest Breast Screening Performance Data 2021-2022, Chief Executive at Breast Cancer Now, Baroness Delyth Morgan, said:
17 Feb 2023
Breast Cancer Now responds to research about radiotherapy and older women with early breast cancer
In response to research published in the New England Journal of Medicine* about radiotherapy, Dr Kotryna Temcinaite, senior research communications manager at Breast Cancer Now, said:
16 Feb 2023
Breast Cancer Now responds to Cancer Research UK’s estimate that the number of people diagnosed with cancer will ‘rise by a third by 2040’
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
03 Feb 2023
Breast Cancer Now respond to Wales Cancer Networks’ Cancer Improvement Plan
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
31 Jan 2023